

The Pfizer Intelligence Dossier

<https://marketpublishers.com/r/P0555162466EN.html>

Date: October 2009

Pages: 60

Price: US\$ 295.00 (Single User License)

ID: P0555162466EN

Abstracts

In boardrooms, around water coolers and behind closed office doors, decision-makers in the pharmaceutical industry are asking questions: What's happening with Pfizer? What developments have occurred in the last quarter? And how will it affect us?

With Pfizer's recent US\$68 billion acquisition of Wyeth, it's not surprising. While the multinational giant has refused to seed speculation about potential cuts to its immediate R&D budget, early indications from the combined company suggest it will narrow its focus to cancer, neurological disease, disorders, pain therapy, diabetes, heart and circulatory disease, antibacterial agents and vaccines.

Even more compelling, however, is that the company's third quarter of 2009 began with news of a 19 per cent drop in second-quarter profit to \$2.3 billion, due to a series of missteps and lost patent protections that will inevitably lead to generic brand competition internationally. According to Morgan Stanley investment analysts, "investors have given up on Pfizer's pipeline after a series of failures over the last two years". Overshadowing that development is major litigation involving Bextra and Neurontin. Yet despite that, the company retains a strong position, with the majority of news reports analyzed as positive.

So what is happening with Pfizer? In a word, plenty. But the real question is: How are you going to keep track of it all?

Key insights on critical industry developments

FirstWord's new series of Company Intelligence Dossiers provides an overview of Q3 developments in the Pfizer universe, including a detailed snapshot of its position from a financial, corporate, international and R&D point of view. The report analyzes 110 articles published in the media about Pfizer in the third quarter by topic and impact –

positive, neutral or negative -- on brand perception as well as what underlies those views, to keep you updated on the company's strengths and weaknesses.

The report reviews Pfizer's Q3 progress to establish:

The company's current financial, corporate and public outlook and position

An overview of key developments to give competitors critical information

The report

Offers a concise, visual breakdown of 110 news reports published during the third quarter, analyzed by topic, sentiment and topic addressed

Outlines key negatives in reporting, such as profit drops, generic brand approvals of Viagra, Cleocin, Lipitor and Ellence, as well as current litigation

Reviews major global mergers and acquisitions, including the Wyeth takeover, stake holdings in India, initiatives in China and the Nigerian compensation settlements

Examines R&D as well as marketing news for a wide range of compounds

Provides substantial financial, product and R&D collaterals to put developments in perspective

Critical information included in the report

Key patent expiry dates

Revenue performance by product line

R&D developments by location, product and disease portfolio

International news briefs

Corporate and financial new briefs

Contents

PFIZER INC

Recent Financial Results, 2004-2008

NEWS ANALYSIS

NEWS BREAKDOWN

RECENT DEVELOPMENTS

Corporate

Mergers/Acquisitions

Germany

Brazil

Financials

Pfizer

Wyeth

International Developments

Nigeria

India

China

Philippines

South Korea

Venezuela

Slovenia

European Union

Research & Development

Celsentri/Selzentry (maraviroc)

Drug Candidates

Sutent (sunitinib)/Relistor (methylnaltrexone)

PF-02341066

Aromasin (exemestane)

Pain Disorder Compounds

Oncology Portfolio

Karo Bio

Spiriva (tiotropium)

General Pipeline

Torisel (temsirolimus)/Sutent (sunitinib)

PF-03187207

Relistor (methylnaltrexone)

Dimebon (latrepirdine)

PF-04360365/dimebon

Revatio (sildenafil)

Investigational Dermatological Molecules

Marketing & Sales

Caduet Combination Tablets (amlodipine besylate and atorvastatin calcium)

Chantix/Champix (varenicline)

Aricept (donepezil)

Prevenar 13 (Pneumococcal Conjugate Vaccine 13 Valent [Diphtheria CRM197 Protein])

Cleocin (clindamycin)

Diflucan (fluconazole)

PfizerPen G

Idamycin PFS (idarubicin)

Fablyn (lasofoxifene)

rifabutin

Ellence (epirubicin)

Norvasc (amlodipine)

Regulatory Affairs

Health Plan

Wisconsin Fraud Case

Bextra (valdecoxib)

Neurontin (gabapentin)

Lobbying

Reimportation

Co-pay subsidies

Wyeth Acquisition

Strategic Overview

Structure

Operating Structure

Regulatory Progress

Pfizer - Background Information

Key Products

Key Patent Expiry Dates

Revenues Performance – By Product Line

R&D

Groton & New London, Connecticut
Sandwich, United Kingdom
La Jolla, California
St. Louis, Missouri
Rinat, South San Francisco, California
Cambridge, Massachusetts
Ringaskiddy, Cork, Ireland
Mission Bay
Sweden
R&D Portfolio

INDEX

APPENDIX

I would like to order

Product name: The Pfizer Intelligence Dossier

Product link: <https://marketpublishers.com/r/P0555162466EN.html>

Price: US\$ 295.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P0555162466EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970